Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osi-7904. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS known ✓ | P04818 | 11/20 | 1.00 |
| ▸ | DHFR | P00374 | 3/20 | 0.54 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osi-7904 SCHEMBL2195534 | 1.00 | TYMS (1.00) | TYMSDHFRSLC19A1 | |
| Osi-7904 SCHEMBL29389995 | 1.00 | TYMS (1.00) | TYMSDHFRSLC19A1 | |
| Osi-7904 SCHEMBL29692323 | 1.00 | TYMS (1.00) | TYMSDHFRSLC19A1 | |
| Osi-7904 SCHEMBL29692303 | 1.00 | TYMS (1.00) | TYMSDHFRSLC19A1 | |
| SCHEMBL6446111 | 0.91 | TYMS (0.84) | TYMSDHFRSLC19A1 | |
| SCHEMBL6446103 | 0.91 | TYMS (0.84) | TYMSDHFRSLC19A1 | |
| SCHEMBL2638076 | 0.90 | TYMS (0.81) | TYMSDHFRSLC19A1 | |
| SCHEMBL6447845 | 0.90 | TYMS (0.81) | TYMSDHFRSLC19A1 | |
| SCHEMBL6447840 | 0.90 | TYMS (0.81) | TYMSDHFRSLC19A1 | |
| Osi-7904 SCHEMBL1649579 | 0.88 | TYMS (0.79) | TYMSDHFRSLC19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0909184-B1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | UPJOHN CO (US) | 2003-09-17 | — | — | EP | claimed |
| EP-0675719-B1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | WELLCOME FOUND (GB) | 1998-06-10 | — | — | EP | claimed |
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-02-11 | — | — | US | disclosed |
| US-11219622-B2 | Folate receptor binding conjugates of antifolates | ENDOCYTE, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| EP-3749313-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3749321-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| US-20200360389-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2020-11-19 | — | — | US | disclosed |
| US-20200147072-A1 | Folate Receptor Binding Conjugates of Antifolates | PURDUE RESEARCH FOUNDATION (US) | 2020-05-14 | — | — | US | disclosed |
| WO-2019157148-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019157146-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | disclosed |
| US-10363250-B2 | Folate receptor binding conjugates of antifolates | ENDOCYTE, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9549992-B2 | Folate receptor binding conjugates of antifolates | PURDUE RESEARCH FOUNDATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160263237-A1 | Folate Receptor Binding Conjugates of Antifolates | PURDUE RESEARCH FOUNDATION (US) | 2016-09-15 | — | — | US | disclosed |
| US-9192682-B2 | Folate receptor binding conjugates of antifolates | ENDOCYTE, INC. (IN) | 2015-11-24 | — | — | US | disclosed |
| US-20140213760-A1 | Folate Receptor Binding Conjugates of Antifolates | ENDOCYTE, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8546425-B2 | Folate receptor binding conjugates of antifolates | PURDUE RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2010033733-A1 | FOLATE RECEPTOR BINDING CONJUGATES OF ANTIFOLATES | ENDOCYTE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-6358952-B1 | SIDE EFFECT REDUCTION WHEN ADMINISTERING NON-COMPETITIVE THYMIDYLATE SYNTHASE INHIBITOR AS ANTITUMOR AGENT | SMITHKLINE BEECHAM CORPORATION | 2002-03-19 | — | — | US | disclosed |
| US-6090941-A | Pharmaceutically active benzoquinazoline compounds | GLAXO WELLCOME INC. (US) | 2000-07-18 | — | — | US | disclosed |
| WO-1994014448-A1 | NOVEL COMBINATION OF BENZOQUINAZOLINE ANTIFOLATES AND PROTECTING AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213760-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | TYMS 29/4885DHFR 3/4885SLC19A1 4/4885 |
| US-20200147072-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | TYMS 29/4885DHFR 3/4885SLC19A1 4/4885 |
| US-20160263237-A1 | Folate Receptor Binding Conjugates of Antifolates | FOLR1, FOLR2, DHFR | TYMS 29/4885DHFR 3/4885SLC19A1 4/4885 |
| US-12220431-B2 | Gamma polyglutamated antifolates and uses thereof | GGCT, IFNG, FPGS | TYMS 62/4885DHFR 14/4885SLC19A1 53/4885 |
| US-11219622-B2 | Folate receptor binding conjugates of antifolates | FOLR1, FOLR2, DHFR | TYMS 29/4885DHFR 3/4885SLC19A1 4/4885 |
| US-10363250-B2 | Folate receptor binding conjugates of antifolates | FOLR1, FOLR2, DHFR | TYMS 105/4885DHFR 3/4885SLC19A1 4/4885 |
| US-20200360389-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | TYMS 62/4885DHFR 14/4885SLC19A1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.